arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Foghorn Therapeutics Inc.

FHTX
$3.88 ▼ -0.38 (-8.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

Foghorn Therapeutics Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $274.0M
Dividend Yield
Revenue Growth 112.7%
Op. Margin -54.8%
ROIC 8.6%
FCF / Share $-0.25
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.07M
↑ +112.7%
Net Income Profit after all expenses
$-19.88M
↓ -5.5%
Operating Margin Operating profit as % of sales
-54.8%
↑ +78.8% 0th
FCF / Share Free cash flow per share
$-0.25
↑ +30.3%
Long-Term Debt Long-term obligations
$19.91M
— +0.4%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
98
Cash Quality
71

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 30 quarters